Acute wheezing/bronchiolitis
Conditions
Brief summary
Primary endpoints are 1) the time to a new physician-confirmed wheezy episode, and 2) time to fullfill astma criteria defined as need for a regular controller medication for asthma within 24 months after study entry.
Detailed description
1) Determined at the first episode of acute breathing difficulty within 24 months of study entry: a) duration and severity of symptoms. 2) Determined at each scheduled follow-up visit within 24 months of study entry: a) number, duration and severity of episodes with acute breathing difficulty since start of study medication, b) degree of pulmonary hyperreactivity, c) quality of life, d) height and weight
Interventions
DRUGPlacebo tablets identical to dexamethasone Abcur 1.0 mg tablets
DRUGDEXAMETHASONE
Sponsors
St. Olavs Hospital HF
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints are 1) the time to a new physician-confirmed wheezy episode, and 2) time to fullfill astma criteria defined as need for a regular controller medication for asthma within 24 months after study entry. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Determined at the first episode of acute breathing difficulty within 24 months of study entry: a) duration and severity of symptoms. 2) Determined at each scheduled follow-up visit within 24 months of study entry: a) number, duration and severity of episodes with acute breathing difficulty since start of study medication, b) degree of pulmonary hyperreactivity, c) quality of life, d) height and weight | — |
Countries
Finland, Norway, Sweden
Outcome results
None listed